How BioGenes Supports Your SARS-CoV-2 Research
Since its discovery in late December 2019 in Wuhan (China), SARS-CoV-2 has been detected all over the world, including several variants. It is unique in terms of its high transmissibility, pathogenicity and mortality when compared to other coronaviruses.
BioGenes is participating in the global fight against COVID-19 by providing its knowledge and established technology in highly sophisticated antibody development for diagnostic purposes and research.
SARS-CoV-2 S1-RBD ELISA
To facilitate your SARS-CoV-2 research and process control, BioGenes has found a strong partner in trenzyme, a German Contract Research Organization offering a wide range of highly customized cell and protein services. Both companies have combined their unique expertise and developed a ELISA reagent set for the quantitative in-vitro measurement of SARS- CoV-2 S1-RBD in process samples.
Technical Details
- Assay working range: 0,781 ng/mL - 50 ng/mL
- No cross-reactivity against CHO-S and Hek293-F
- ELISA Standard: SARS-CoV-2 S1 (RBD, tag-free)
- Also usable for the detection of His-tagged SARS-CoV-2 S1-RBD protein with comparable sensitivity